Stockscreener 앱 받기
6.5591
1.57%
-0.1109
전일 마감가:
$6.67
열려 있는:
$6.64
하루 거래량:
1.95M
Relative Volume:
0.62
시가총액:
$2.28B
수익:
$493.67M
순이익/손실:
$-104.69M
주가수익비율:
-19.29
EPS:
-0.34
순현금흐름:
$-31.51M
1주 성능:
-11.16%
1개월 성능:
-12.47%
6개월 성능:
-44.08%
1년 성능:
-36.88%
1일 변동 폭
$6.50
$6.73
1주일 범위
$6.50
$7.705
52주 변동 폭
$6.20
$12.65
아미쿠스 테라 Stock (FOLD) Company Profile
명칭
Amicus Therapeutics Inc
전화
(609) 662-2000
주소
47 HULFISH STREET, PRINCETON, NJ
FOLD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
6.565 | 2.28B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.24 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.27 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.33 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.66 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.47 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
아미쿠스 테라 Stock (FOLD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | 개시 | Jefferies | Buy |
| 2024-05-30 | 개시 | Wells Fargo | Overweight |
| 2024-05-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-04-13 | 재개 | Goldman | Neutral |
| 2022-01-14 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-30 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-07-19 | 재개 | BTIG Research | Buy |
| 2021-05-27 | 개시 | Needham | Hold |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-14 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | 개시 | Stifel | Hold |
| 2021-02-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-28 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-12-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-11-11 | 개시 | Berenberg | Hold |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-02-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-11-12 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-17 | 개시 | H.C. Wainwright | Buy |
| 2019-06-05 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-04-05 | 개시 | Janney | Buy |
| 2019-01-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-10-29 | 개시 | Citigroup | Neutral |
| 2018-08-17 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
| 2017-09-13 | 재확인 | Chardan Capital Markets | Buy |
| 2017-08-10 | 재확인 | Chardan Capital Markets | Buy |
| 2017-01-24 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | 개시 | BofA/Merrill | Buy |
| 2016-04-14 | 개시 | Robert W. Baird | Neutral |
| 2016-04-12 | 재확인 | Chardan Capital Markets | Buy |
| 2015-09-16 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | 재확인 | Chardan Capital Markets | Buy |
모두보기
아미쿠스 테라 주식(FOLD)의 최신 뉴스
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by Aquatic Capital Management LLC - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by PDT Partners LLC - MarketBeat
Tower Research Capital LLC TRC Boosts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Marshall Wace LLP Grows Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Dark Forest Capital Management LP Purchases Shares of 38,148 Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Voya Investment Management LLC Lowers Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
UBS Raises Price Target for Amicus Therapeutics (FOLD) to $22, M - GuruFocus
Amicus Therapeutics (FOLD) Target Price Lowered by Goldman Sachs | FOLD Stock News - GuruFocus
FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls - TradingView
UBS Boosts Amicus (FOLD) Price Target Despite Revised Pompe Dise - GuruFocus
UBS Boosts Amicus (FOLD) Price Target Despite Revised Pompe Disease Outlook | FOLD Stock News - GuruFocus
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2025 Earnings Call Transcript - Insider Monkey
UBS Adjusts Amicus Therapeutics Price Target to $22 From $21, Maintains Buy Rating - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
Dimerix and Amicus to commercialise DMX-200 in US - MSN
Amicus Therapeutics Inc Reports Q1 2025 Earnings: EPS of -$0.07 - GuruFocus
Dimerix strikes $601M Amicus deal for kidney disease drug DMX-200 - BioWorld MedTech
Dimerix and Amicus Therapeutics Announce Exclusive License Agree - GuruFocus
Amicus Therapeutics Turns to Non-GAAP Q1 Earnings, Revenue Rises; Shares Down - marketscreener.com
Earnings call transcript: Amicus Therapeutics reports Q1 2025 loss, stock drops - Investing.com India
Amicus Therapeutics (FOLD) Q1 Earnings and Revenues Lag Estimates - Yahoo Finance
Amicus Therapeutics: Q1 Earnings Snapshot - San Antonio Express-News
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates - The Manila Times
Amicus Therapeutics Q1 2025 slides: 15% revenue growth, new kidney disease program - Investing.com
Amicus (FOLD) Shows Strong Revenue Growth Amid Recent Quarter Ch - GuruFocus
BRIEF-Amicus Therapeutics Q1 Revenue USD 125.2 Million Vs. IBES Estimate USD 135.9 Million - TradingView
Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Target Price at $16.75 - MarketBeat
Amicus Therapeutics Signs Exclusive License Deal for Dimerix Kidney Disease Therapy - marketscreener.com
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States - GlobeNewswire
Amicus Therapeutics Q1 2025 Earnings Preview - MSN
Amicus Therapeutics Earnings Preview - Nasdaq
Fabry Disease Market: Epidemiology, Drugs, Companies, DelveInsight | Amicus Therapeutics, CHIESI Farmaceutici and Protalix Biotherapeutics, Sanofi (Genzyme), Takeda Pharmaceuticals, Sangamo Therapeuti - The Globe and Mail
LATAM Fabry Disease Market Set to Witness Significant Growth - openPR.com
Amicus Therapeutics (FOLD) to Release Earnings on Thursday - MarketBeat
Russell Investments Group Ltd. Grows Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Rock Springs Capital Management LP Purchases 1,349,145 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Jump Financial LLC Lowers Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics to Report Q1 Earnings: What's in the Cards? - MSN
Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Is Amicus Therapeutics, Inc. (FOLD) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Insider Monkey
아미쿠스 테라 (FOLD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
0.30%
자본화:
|
볼륨(24시간):